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HIV-ASSOCIATED PULMONARY HYPERTENSION: CASE REPORT
J. SHAVADIA, S. DAS and G. YONGA
SUMMARY
With the advent of highly active antiretroviral therapy, there has been a signiﬁcant change
in the epidemiology of pulmonary disease in HIV/AIDS. The relative prevalence of
non-infectious manifestations is likely to rise. HIV associated pulmonary hypertension
(HIV-PH), albeit low prevalence, is associated with signiﬁcant morbidity and mortality.
Presently, despite having scanty evidence on the management modalities of HIV-PH,
evidence extrapolated from idiopathic pulmonary hypertension is being utilised to
effectively manage some of these patients. Efforts should therefore be made to screen,
diagnose and treat these patients. A case of a thirty year old female with HIV disease
and severe pulmonary hypertension is presented.

INTRODUCTION
Since the description of HIV associated pulmonary
hypertension (HIV-PH) by Kim and Factor in 1987,
the prevalence of HIV-PH has been reported to be
between 0.06-2% (1). This is far less common compared
to the infectious complications associated with HIV
disease. However, with widespread antiretroviral
therapy (ART) rollout programmes, more people are
now living with HIV hence the relative prevalence of
non-infectious complications related to HIV disease
are likely to increase.
HIV-PH has been documented to occur at all
stages of the disease and its manifestations range
from asymptomatic right ventricular dysfunction
to overt right heart failure. There have been no
large scale studies on the effects of ART on HIV-PH.
Most treatment modalities currently in place are an
extension of evidence from trials used to manage
idiopathic pulmonary hypertension.
We present a case of HIV-PH to highlight
the importance of the non infectious pulmonary
complications associated with HIV disease.
CASE REPORT
A thirty year old female presented with an eight month
history of progressively increasing shortness of breath
at The Aga Khan University Hospital, Nairobi on the
29th January 2008. She also reported associated lower
limb swelling, facial pufﬁness and difﬁculty in lying
on a ﬂat bed. In the last month prior to her admission,
the shortness occurred even during bathing and

dressing. She also had a nocturnal non productive
cough. She was para 3+0 and all her pregnancies
were uneventful. She denied any history of a wheeze,
haemoptysis, rash, oral or genital sores. She had no
history of febrile illness, night sweats or weight loss.
She had been started on frusemide and candensartan
for presumed heart failure at the nearest health facility
and reported temporary relief of symptoms, until one
month prior to presentation.
Examination revealed an afebrile ill looking
young lady whose vital signs were as: BP 110/62mmHg
supine, P 132 bpm regular, of low volume and normal
character, RR 20 breaths/ min. General examination
revealed oral candidiasis and bipedal lower limb
pitting oedema. No joint swelling or deformity and
no skin rashes were found.
Pertinent cardiovascular ﬁndings included an
elevated jugular venous pulsation with a prominent v
wave. Her apex beat was undisplaced and her cardiac
impulse felt normal. She had a left lower parasternal
lift and a palpable P2. Cardiac auscultation conﬁrmed
a loud P2 and a pansystolic murmur in the left lower
sternal border which was accentuated on inspiration.
The rest of her systemic exam was non contributory.
A clinical diagnosis of right heart failure with
pulmonary hypertension and immunosuppression
was made.
A resting l2-lead ECG demonstrated an
incomplete right bundle branch block and evidence
of right atrial overload. Echocardiogram revealed a
moderately enlarged right ventricle and atrium with
paradoxical septal motion. She had moderate- severe
tricuspid regurgitation with an estimated pulmonary
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arterial pressure of 80mmHg. Her left ventricular
ejection fraction was 50% with normal mitral and
tricuspid valve anatomy. No atrial septal defect or
any other cardiac shunts were found.
Full blood count and ESR, renal and liver
functions were normal, and her peripheral blood
ﬁlm did not reveal any evidence of an underlying
haemolytic disorder. After counselling and testing,
an ELISA for HIV was positive, CD4 count was
312cells/mm3 and a plasma viral load 75,000 copies/
mm3. She was hepatitis B surface antigen negative.
A CT pulmonary angiogram ruled out pulmonary
thromboembolic disease.
She was commenced on diuretics, antifungals,
anticoagulation and later sildenaﬁl introduced. She
experienced signiﬁcant symptomatic improvement.
On the ﬁfth hospitalisation day the patient was able
to ambulate freely in the ward, and perform her
personal activities without signiﬁcant limitation. She
was discharged home on 5th February 2008, eight
days after hospitalisation on frusemide, warfarin,
tenofovir/emtricitabine and efavirenz.
On out-patient follow up three months later,
the patient reported to be able to climb two ﬂights
of stairs and perform her activities of daily living
comfortably. She was to have an echocardiogram
repeated in 12 months from her initial presentation
for estimation of her pulmonary arterial pressures
as a follow up of the efﬁcacy of treatment. The
frequency of echocardiographic follow-up was
based on the patient living away from Nairobi,
and concomitant ﬁnancial strain on performing six
monthly echocardiographic assessments. However,
improvement in her dyspnoea severity, as assessed by
her New York Heart Association criteria, about three
months into therapy is a strong clinical indicator of
therapeutic efﬁcacy and this parameter in addition
to yearly echocardiography will be utilised for her
follow up.
DISCUSSION
Pulmonary hypertension (PH) is a relentlessly
progressive disease leading to right heart failure and
death. With a worldwide prevalence of HIV disease
estimated at 40 million (2), and that of HIV-PH at 0.062.0% (1), HIV disease may be among the most common
cause of pulmonary hypertension worldwide.
Reports from other parts of Africa, however,
suggest a much higher prevalence of HlV-PH at about
5% (3). This goes to reﬂect the potential magnitude of
HIV -PH in sub Saharan Africa, which houses over
two-thirds of the global HIV burden (4). Despite these
alarming ﬁgures, a pubmed search did not reveal
any citations from Kenya on the prevalence of this
complication associated with HIV disease.
A diagnosis of HIV-PH was made in this
patient after exclusion of the common secondary
causes of PH, as connective tissue disease, chronic
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thromboembolic disease and haemolytic anaemias.
Due to the age bracket the index patient presented
in, connective tissue disease fell high on the list.
However, her clinical history, physical examination
and supportive laboratory and radiological evidence
were not in keeping for a connective tissue disease,
chronic thromboembolism or haemolytic anaemias.
Since the potential causes for PH are numerous and
investigations to rule out each would be superﬂuous,
it is imperative to obtain a good clinical history and
perform a thorough clinical evaluation to narrow
the differential causative agents as performed in this
patient.
Pulmonary arterial hypertension, of which
HIV -PH is a sub entity, deﬁnes an increase in mean
pulmonary arterial pressure related to an arteriopathy
of the pulmonary vasculature. Patients with HIV -PH
have plexogenic lesions similar to diseases associated
with pulmonary arterial hypertension.
Majority of the patients clinically present with
dyspnoea on exertion (85%), pedal oedema (20-30%)
and a non-productive cough (19%). The interval
duration between symptom development and
diagnosis is reported at six months (5). This data
is in line with the clinical symptoms and duration
between symptom onset and diagnosis in the index
patient. There is also no correlation between the CD4
count or plasma viral load and the development of
HIV-PH (6,7).
In terms of pathogenetic mechanisms, there is
no evidence incriminating human immunodeﬁciency
virus (HIV) to be directly infecting pulmonary
vascular endothelial cells (8,9). However, viral
antigens such as GP120 and Nef, are thought to
stimulate growth and proliferation (8,10,11). The
other plausible mechanism includes induction
by HIV infection of a chronic inﬂammatory state
with release of growth promoting cytokines which
stimulate smooth muscle hypertrophy and increase
pulmonary vascular resistance (12,13).
Treatment of patients with HIV-PH is based on
symptomatology, functional class and the severity of
PH. Although vasodilator agents increase survival in
patients with idiopathic pulmonary hypertension,
the impact of these therapies on HIV-PH is unknown
(14,15).
Nunes et al (l6) reported better survival in
patients on epoprostenol infusion. In another
smaller study, Petitpretz et al (6) also reported
signiﬁcant improvement in the haemodynamics in
patients on epoprostenol. Epoprostenol has well
described adverse effects, as well as its difﬁculty
in administration. We therefore chose sildenaﬁl, a
phosphodiesterase-5-inhibitor, which has shown
some short term efﬁcacy in case reports of patients
with HIV-PH (17-19). A potential problem with
sildenaﬁl is that its levels may signiﬁcantly increase
by concurrent use of protease inhibitors, hence the
choice of efavirenz in our patient.
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The other potential choice to reduce pulmonary
arterial pressure would include endothelin antagonists,
as bosentan. Like all the other agents, scanty data exists
in HIV-PH (20-22). In view of this, its unavailability
in our region, and the exorbitant costs of the drug,
our patient was not started on it.
Figure 1
Apical 4 chamber view demostrating an enlarged right
atrium and enlarged right atrium and ventricle

This case highlights the presence of HIV-PH
whose mortality is two fold higher in HIV patients
without pulmonary hypertension (23). It also brings
to the fore the potential problems our HIV patients
may now present with, since a large proportion of
patients on HAART are now living much longer
with HIV disease. It also calls for larger studies in
our region to build up regional evidence in order to
better the management of such patients.
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